% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Herrmann:304585,
      author       = {K. Herrmann$^*$ and J. Walz and S. MacLennan and A.
                      Briganti and P. Cornford and J. Czernin and M. Eiber and S.
                      Fanti and W. P. Fendler$^*$ and K. Fizazi and A. Gafita and
                      S. Gillessen and K. Goffin and B. Hadaschik$^*$ and M. S.
                      Hofman and T. A. Hope and T. Maurer and A. K. Morgans and M.
                      J. Morris and D. G. Murphy and D. E. Oprea-Lager and P. Ost
                      and J. M. ÓSullivan and O. Rouvière and S. Sandhu and O.
                      Sartor and M. M. Sathekge and C. Tempany and W. Witjes and
                      L. Emmett and A. S. Bjartell},
      title        = {{SPARC}: {T}he {S}tandardised {P}rostate-specific
                      {M}embrane {A}ntigen {P}ositron {E}mission
                      {T}omography/{C}omputed {T}omography {A}nalysis and
                      {R}eporting {C}onsensus: {A} {D}elphi {A}nalysis.},
      journal      = {European urology},
      volume       = {nn},
      issn         = {0302-2838},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2025-01908},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Prostate-specific membrane antigen (PSMA) positron emission
                      tomography/computed tomography (PET/CT) is an evolving
                      diagnostic tool for prostate cancer. There is a need to
                      harmonise existing guidelines and reporting recommendations
                      for PSMA PET/CT. The Standardised PSMA PET/CT Analysis and
                      Reporting Consensus (SPARC) project aims to consolidate
                      classifications and recommendations by a multidisciplinary
                      and international group of experts under one cohesive
                      framework, establishing a dynamic and evolving structure for
                      PSMA PET/CT reporting.We employed a cross-sectional
                      iterative process to define opinions and evaluate consensus.
                      Thirty expert panel members, representing diverse
                      specialities and geographic areas, were selected. A methods
                      expert led the design, data collection, and analysis. Five
                      groups of international multidisciplinary prostate cancer
                      experts convened for literature review and formulation of
                      statements on standardised reporting, detection, primary
                      staging, biochemical recurrence, and treatment response. The
                      groups compiled 91 statements for a two-round modified
                      Delphi survey. The 'RAND appropriateness method' was used
                      for the analysis.Consensus increased to $93\%$ between two
                      rounds. The panel endorsed and adopted the following
                      frameworks for reporting of PSMA PET/CT: molecular imaging
                      PSMA for expression level and certainty, miTNM by PROMISE
                      for reporting of PSMA PET/CT, the PRIMARY score for
                      intraprostatic staging, PSMA volume, mean standardised
                      uptake value, and maximum standardised uptake value
                      (SUVmax). There were uncertainty about correlating PSMA
                      PET/CT with conventional imaging risk groups in newly
                      diagnosed metastatic prostate cancer and a lack of agreement
                      that clinical management plans based upon PSMA PET/CT
                      improved outcomes. There was consensus that SUVmax should be
                      reported regionally, rather than reporting a single site.
                      There were insufficient data to standardise a definition of
                      response or progression by PSMA PET/CT.SPARC provides a
                      standardised PSMA PET/CT analysis and reporting consensus to
                      serve as a future reference for PSMA PET/CT reporting.
                      Integration of common PSMA PET reporting criteria under one
                      umbrella improves the explanation of imaging findings
                      between imaging experts and treating clinicians for clinical
                      implementation.},
      keywords     = {Positron emission tomography/computed tomography (Other) /
                      Prostate cancer (Other) / Prostate-specific membrane antigen
                      (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40945999},
      doi          = {10.1016/j.eururo.2025.08.005},
      url          = {https://inrepo02.dkfz.de/record/304585},
}